The J.N. article is significant as he has a large amount of readers and the more important fact is the statement of middle of November for Z160 results. We should more than likely now get the normal band wagon run up to when a small bio is to report results on its trials. As for his pps predictions, who knows. I have had the feeling that Zalicus would be bought out by EOY or early 2014 for 500-700M or somewhere around $25 pps.
This majority of this value would be positive Z160 P2 results but also the two imortant broad range patents they have approved that go out until something like 2025 for 160 &944. There are so many more possible combinations and indications that they can cover. Also they are generating income for Chts, Exalgo, and maybe still Fov1101. Now where did that picture of that fancy hat I am waiting to buy Gina go/+/?